SG10202108723PA - Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation - Google Patents

Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation

Info

Publication number
SG10202108723PA
SG10202108723PA SG10202108723PA SG10202108723PA SG10202108723PA SG 10202108723P A SG10202108723P A SG 10202108723PA SG 10202108723P A SG10202108723P A SG 10202108723PA SG 10202108723P A SG10202108723P A SG 10202108723PA SG 10202108723P A SG10202108723P A SG 10202108723PA
Authority
SG
Singapore
Prior art keywords
apoaequorin
methods
same
containing compositions
neuronal inflammation
Prior art date
Application number
SG10202108723PA
Inventor
Mark Underwood
James MOYER
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of SG10202108723PA publication Critical patent/SG10202108723PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202108723PA 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation SG10202108723PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462078099P 2014-11-11 2014-11-11

Publications (1)

Publication Number Publication Date
SG10202108723PA true SG10202108723PA (en) 2021-09-29

Family

ID=55954981

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703690XA SG11201703690XA (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation
SG10202108723PA SG10202108723PA (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201703690XA SG11201703690XA (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation

Country Status (24)

Country Link
US (1) US20180214516A1 (en)
EP (1) EP3217998B1 (en)
JP (1) JP6861162B2 (en)
KR (1) KR20170072350A (en)
CN (1) CN107106649A (en)
AU (2) AU2015346430B2 (en)
BR (1) BR112017009599A2 (en)
CA (1) CA2966891C (en)
DK (1) DK3217998T3 (en)
ES (1) ES2910021T3 (en)
HK (2) HK1243343A1 (en)
HR (1) HRP20220749T1 (en)
HU (1) HUE059107T2 (en)
IL (1) IL252070B (en)
LT (1) LT3217998T (en)
MA (1) MA40959A (en)
MX (1) MX2017006063A (en)
NZ (1) NZ731340A (en)
PL (1) PL3217998T3 (en)
PT (1) PT3217998T (en)
RS (1) RS63269B1 (en)
SG (2) SG11201703690XA (en)
SI (1) SI3217998T1 (en)
WO (1) WO2016077437A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190365854A1 (en) 2016-09-23 2019-12-05 Quincy Bioscience, Llc Apoaequorin and vitamin d-containing compositions and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ214563A (en) * 1984-12-31 1991-05-28 Univ Georgia Production of apoaeqorin using recombinant dna
MX2010009753A (en) * 2008-03-11 2010-09-30 Quincy Bioscience Llc Apoaequorin-containing compositions and methods of using same.
US20110130336A1 (en) 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
MX350259B (en) * 2011-11-15 2017-08-31 Quincy Bioscience Llc Apoaequorin for reducing neuronal injury due to ischemia.
US20150246101A1 (en) * 2012-09-27 2015-09-03 Mark Y. Underwood Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions

Also Published As

Publication number Publication date
HK1243343A1 (en) 2018-07-13
IL252070B (en) 2022-06-01
ES2910021T3 (en) 2022-05-11
LT3217998T (en) 2022-04-11
AU2015346430A1 (en) 2017-05-25
AU2015346430B2 (en) 2019-01-03
NZ731340A (en) 2018-11-30
HK1244223A1 (en) 2018-08-03
PL3217998T3 (en) 2022-07-11
US20180214516A1 (en) 2018-08-02
DK3217998T3 (en) 2022-04-25
AU2018279057A1 (en) 2019-01-17
CA2966891A1 (en) 2016-05-19
PT3217998T (en) 2022-04-05
EP3217998B1 (en) 2022-03-23
MA40959A (en) 2017-09-19
IL252070A0 (en) 2017-07-31
RS63269B1 (en) 2022-06-30
EP3217998A4 (en) 2018-06-27
MX2017006063A (en) 2017-07-27
WO2016077437A1 (en) 2016-05-19
BR112017009599A2 (en) 2017-12-19
SG11201703690XA (en) 2017-06-29
EP3217998A1 (en) 2017-09-20
JP6861162B2 (en) 2021-04-21
CA2966891C (en) 2023-07-04
KR20170072350A (en) 2017-06-26
HUE059107T2 (en) 2022-10-28
CN107106649A (en) 2017-08-29
HRP20220749T1 (en) 2022-09-02
JP2017535607A (en) 2017-11-30
SI3217998T1 (en) 2022-07-29

Similar Documents

Publication Publication Date Title
IL251066A0 (en) Compositions and methods of use for treating metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
ZA201607540B (en) Compositions and methods to treating hemoglobinopathies
HUE065662T2 (en) Compositions and methods relating to the treatment of diseases
HK1243325A1 (en) Compositions and methods to treat vision disorders
LT3189074T (en) Compositions and methods for treating and preventing inflammation
HK1247789A1 (en) Compositions and methods for treatment of edema
HK1244711A1 (en) Treatment of hmgb1-mediated inflammation
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
GB201617622D0 (en) Means and methods to treat inflammation
HK1244223A1 (en) Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation
GB201516303D0 (en) Compositions and methods relating to the treatment of diseases